Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,549 active trials61 approved drugs295 evidence items
- NCIt
- C156484
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05773859 | NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer(NEODOC) | recruiting | Phase 1 / Phase 2 | 10 | Radboud University Medical CenterOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT07163910 | Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinical Study | recruiting | Phase 2 | 93 | baotai LiangOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT05997017 | Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer | recruiting | Phase 2 | 29 | Aadi Bioscience, Inc.INDUSTRY | 1 | Nov 13, 2025 | clinicaltrials |
| NCT06601296 | Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer(SPARK) | recruiting | Phase 2 | 15 | University of Texas Southwestern Medical CenterOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT07225374 | Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUC | recruiting | Phase 2 | 48 | Samsung Medical CenterOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT06677190 | Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin | recruiting | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT04724018 | Sacituzumab Govitecan Plus EV in Metastatic UC | recruiting | Phase 1 / Phase 2 | 106 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT05902988 | A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | recruiting | Phase 1 / Phase 2 | 200 | Volastra Therapeutics, Inc.INDUSTRY | 1 | Nov 4, 2025 | clinicaltrials |
| NCT06481592 | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer. | recruiting | Phase 2 | 60 | Iovance Biotherapeutics, Inc.INDUSTRY | 1 | Oct 30, 2025 | clinicaltrials |
| NCT06617923 | Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer | recruiting | Phase 2 | 18 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 27, 2025 | clinicaltrials |
| NCT05512208 | A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib(DURAFAK) | recruiting | Phase 2 | 55 | University of OklahomaOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT06005818 | Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)(MRD GATE RCC) | recruiting | Phase 2 | 100 | University of Alabama at BirminghamOTHER | 1 | Oct 21, 2025 | clinicaltrials |
| NCT05931393 | Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC) | recruiting | Phase 2 | 18 | University of Texas Southwestern Medical CenterOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT07209878 | 68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI | recruiting | Phase 2 / Phase 3 | 100 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT05869682 | Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy | recruiting | Phase 2 | 210 | City of Hope Medical CenterOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT04644289 | WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC(WoO) | recruiting | Phase 2 | 60 | AGO Research GmbHINDUSTRY | 1 | Oct 3, 2025 | clinicaltrials |
| NCT00722228 | Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors | recruiting | Phase 1 / Phase 2 | 50 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05296564 | Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers | recruiting | Phase 1 / Phase 2 | 3 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05346848 | Randomized Phase II Trial on Short Term Darolutamide Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer(DARIUS) | recruiting | Phase 2 | 62 | Institut BergoniéOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05965856 | A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors | recruiting | Phase 2 | 52 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05990803 | A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies | recruiting | Phase 2 | 130 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT04678362 | TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma(TALASUR) | recruiting | Phase 2 | 50 | Centre Francois BaclesseOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT07179783 | Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC) | recruiting | Phase 2 | 28 | Tianjin Medical University Second HospitalOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT05329532 | Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer(ModiFY) | recruiting | Phase 1 / Phase 2 | 168 | Scancell LtdINDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT06152731 | HRD Tests for Ovarian cancER(HERO) | recruiting | Phase 2 | 88 | Centre Francois BaclesseOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT07172386 | Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC | recruiting | Phase 2 | 40 | Tianjin Medical University Second HospitalOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT07175480 | PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk(Perfumer) | recruiting | Phase 2 | 30 | Jinling Hospital, ChinaOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT07171528 | Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer(KOV-02S) | recruiting | Phase 2 | 80 | National Cancer Center, KoreaOTHER_GOV | 1 | Sep 12, 2025 | clinicaltrials |
| NCT05998135 | Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer | recruiting | Phase 2 | 28 | Emory UniversityOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT07055399 | Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE-CC)(NICE-CC) | recruiting | Phase 2 | 43 | Fujian Cancer HospitalOTHER_GOV | 1 | Sep 11, 2025 | clinicaltrials |
| NCT06302569 | Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma(REPRINT) | recruiting | Phase 2 | 23 | Giuseppe ProcopioOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06682793 | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression(DENALI-1) | recruiting | Phase 1 / Phase 2 | 240 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06255223 | A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy | recruiting | Phase 2 | 35 | Jinling Hospital, ChinaOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT06689163 | A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone | recruiting | Phase 1 / Phase 2 | 66 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 3, 2025 | clinicaltrials |
| NCT06571708 | Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)(NeoSTOP-IT) | recruiting | Phase 2 | 36 | Columbia UniversityOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT05879653 | Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD) | recruiting | Phase 2 | 30 | Kyoto University HospitalOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT03878849 | Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer | recruiting | Phase 2 | 40 | Allarity TherapeuticsINDUSTRY | 1 | Aug 28, 2025 | clinicaltrials |
| NCT06134232 | Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T(ProvONE) | recruiting | Phase 2 | 400 | DendreonINDUSTRY | 1 | Aug 27, 2025 | clinicaltrials |
| NCT06241846 | A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC | recruiting | Phase 2 | 100 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Aug 27, 2025 | clinicaltrials |
| NCT06683846 | Ivonescimab in the Treatment of Multiple Advanced Tumors | recruiting | Phase 2 | 400 | Fudan UniversityOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT05113368 | Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer | recruiting | Phase 2 | 31 | Sarah K. Lynam MDOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT07130240 | Ivonescimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy Followed by Type A Hysterectomy in Stage IB2 and IIA1 Cervical Cancer | recruiting | Phase 2 | 20 | Obstetrics & Gynecology Hospital of Fudan UniversityOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT07126119 | Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC | recruiting | Phase 2 | 35 | Tianjin Medical University Second HospitalOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT06983210 | Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma(GRAPE) | recruiting | Phase 2 | 43 | Nagoya UniversityOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT07122414 | A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer | recruiting | Phase 1 / Phase 2 | 80 | Suzhou Forlong Biotechnology Co., LtdINDUSTRY | 1 | Aug 14, 2025 | clinicaltrials |
| NCT06364956 | Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma | recruiting | Phase 1 / Phase 2 | 36 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT07104149 | Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer | recruiting | Phase 2 | 29 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT07097935 | Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 104 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 1, 2025 | clinicaltrials |
| NCT06537154 | NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillance vs Treatment(NEO-BLAST) | recruiting | Phase 2 / Phase 3 | 688 | Peter BlackOTHER | 1 | Jul 30, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Nov 18, 2025source: clinicaltrials